QSYMIA is now approved and available in the United States, South Korea, Sweden, Norway, Poland, Denmark, Iceland, and Finland. The product was recently approved in United Arab Emirates and VIVUS ...

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

GoodRx shares rose 1.5% in premarket trading Tuesday after the healthcare company said it will offer a 30-day supply of oral ...

For more information about the Company, please visit https://www.vivus.com. QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body ...

By making QSYMIA more accessible, GoodRx and Vivus are helping those struggling with weight and obesity find more affordable ...

Collaborative telehealth platform will provide patients with immediate access to QSYMIA®, a chronic weight loss medication, enhancing their ...

VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its weight-management medication QSYMIA (phentermine and ...

QSYMIA is now approved and available in the United States, South Korea, Sweden, Norway, Poland, Denmark, Iceland, and Finland. The product was recently approved in United Arab Emirates and VIVUS is ...

CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its ...